Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Ipilimumab 36Lomustine 35Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × bemcentinib × CNS × Clear all
NCT03965494 2024-02-08

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Terminated
10 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡